Regardless the similarities and differences in the phenotype and genetic background of the PDAC cell lines used in our studies, these results validate our previous findings in an in vivo setting and indicate that MRP4 levels determine pancreatic tumor development, independently of KRAS status. The gene discussed is KRAS; the disease is pancreatic neoplasm.